Clinical Trials
25 trialsNCT03260894 2026-05-22
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT03493945 2025-09-30
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02752074 2025-08-24
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Incyte Corporation
Phase 3 Completed
NCT03322540 2025-08-22
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
Incyte Corporation
Phase 2 Completed
NCT03361865 2025-08-22
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Incyte Corporation
Phase 3 Completed
NCT03374488 2025-08-22
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Incyte Corporation
Phase 3 Completed
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT02042430 2024-12-13
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Completed
NCT03006302 2024-10-08
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03602586 2024-07-26
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03196232 2024-01-23
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Stanford University
Phase 2 Completed
NCT02166905 2023-02-24
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT03589651 2023-02-21
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT02862457 2022-08-19
MK-3475-434
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02178722 2022-02-14
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Phase 1/2 Completed
NCT03322384 2022-02-01
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
University of California, Davis
Phase 1/2 Completed
NCT03322566 2022-01-24
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
Incyte Corporation
Phase 2 Completed
NCT02318277 2022-01-13
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
Incyte Corporation
Phase 1/2 Completed
NCT01961115 2018-06-08
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01195311 2018-01-17
A Dose-escalation Study in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT02118285 2017-12-05
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01822691 2016-01-18
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed